Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

被引：32
|
作者：
Diefenbach, Catherine S. [1 ]
Hong, Fangxin [2 ]
David, Kevin A. [3 ]
Cohen, Jonathon [4 ]
Robertson, Michael [5 ]
Advani, Ranjana [6 ]
Palmisiano, Neil D. [7 ]
Ambinder, Richard F. [8 ]
Kahl, Brad S. [9 ]
Ansell, Stephen [10 ]
机构：
[1] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA
[2] Dana Farber Canc Inst, ECOG ACRIN Biostatist Ctr, Boston, MA USA
[3] Northwestern Univ Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL USA
[4] Emory Univ, Atlanta, GA USA
[5] Indiana Univ Sch Med, Indianapolis, IN USA
[6] Stanford Canc Inst, Stanford, CA USA
[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[8] Johns Hopkins Med Inst, Div Hematol Malignancies, SKCCC, Baltimore, MD USA
[9] Washington Univ, St Louis, MO USA
[10] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1182/blood.V128.22.1106.1106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)
    McNeel, Douglas G.
    Chen, Yu-Hui
    Gulley, James L.
    Dwyer, Alexander J.
    Madan, Ravi A.
    Carducci, Michael A.
    DiPaola, Robert S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (10) : 2469 - 2474
  • [32] Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
    Garcia-Sanz, Ramon
    Sureda, Anna
    Alonso-Alvarez, Sara
    Pilar Gonzalez, Ana
    Rodriguez, Antonia
    Salar, Antonio
    de la Cruz, Fatima
    Domingo, Eva
    Moreno, Miriam
    Lopez, Javier, Sr.
    Luis Pinana, Jose
    Rodriguez, Gabriela
    Canales, Miguel
    Manuel Gurierrez, Antonio
    Lopez-Guillermo, Armando
    Dolores Caballero, Maria
    Jimenez, Silvia
    Martinez, Carmen
    BLOOD, 2015, 126 (23)
  • [33] A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
    Lori J. Goldstein
    Fengmin Zhao
    Molin Wang
    Ramona F. Swaby
    Joseph A. Sparano
    Neal J. Meropol
    Kapil N. Bhalla
    Christine M. Pellegrino
    R. Katherine Alpaugh
    Carla I. Falkson
    Paula Klein
    George W. Sledge
    Breast Cancer Research and Treatment, 2017, 165 : 375 - 382
  • [34] A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
    Goldstein, Lori J.
    Zhao, Fengmin
    Wang, Molin
    Swaby, Ramona F.
    Sparano, Joseph A.
    Meropol, Neal J.
    Bhalla, Kapil N.
    Pellegrino, Christine M.
    Alpaugh, R. Katherine
    Falkson, Carla I.
    Klein, Paula
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (02) : 375 - 382
  • [35] E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group
    Connolly, R.
    Zhao, F.
    Miller, K.
    Tevaarwerk, A.
    Wagner, L.
    Lee, M.
    Murray, J.
    Gray, R.
    Piekarz, R.
    Zujewski, J. A.
    Sparano, J.
    CANCER RESEARCH, 2016, 76
  • [36] E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group
    Connolly, Roisin M.
    Zhao, Fengmin
    Miller, Kathy D.
    Lee, Min-Jung
    Piekarz, Richard L.
    Smith, Karen L.
    Brown-Glaberman, Ursa
    Winn, Jennifer S.
    Faller, Bryan A.
    Onitilo, Adedayo A.
    Burkard, Mark E.
    Budd, George T.
    Levine, Ellis G.
    Royce, Melanie E.
    Kaufman, Peter A.
    Thomas, Alexandra
    Trepel, Jane B.
    Wolff, Antonio C.
    Sparano, Joseph A.
    CANCER RESEARCH, 2021, 81 (04)
  • [37] E2112: Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [38] Randomized Phase 3 Study in Low-Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody With Observation After Induction Therapy: A Trial of the ECOG-ACRIN Cancer Research Group (E1496)
    Barta, Stefan K.
    Li, Hailun
    Hochster, Howard S.
    Hong, Fangxin
    Weller, Edie
    Gascoyne, Randy D.
    Habermann, Thomas M.
    Gordon, Leo I.
    Colocci, Natalia
    Bengtson, Elizabeth M.
    Horning, Sandra J.
    Kahl, Brad S.
    CANCER, 2016, 122 (19) : 2996 - 3004
  • [39] Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205)
    Gibson, Michael K.
    Catalano, Paul
    Kleinberg, Lawrence R.
    Staley, Charles A., III
    Montgomery, Elizabeth A.
    Jimeno, Antonio
    Song, Wei
    Mulcahy, Mary F.
    Leichman, Lawrence P.
    Benson, Al B., III
    ONCOLOGIST, 2020, 25 (01): : E53 - E59
  • [40] A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)
    Zent, Clive S.
    Wang, Xin Victoria
    Ketterling, Rhett P.
    Hanson, Curtis A.
    Libby, Edward N.
    Barrientos, Jacqueline C.
    Call, Timothy G.
    Chang, Julie E.
    Liu, Jane J.
    Calvo, Alejandro R.
    Lazarus, Hillard M.
    Rowe, Jacob M.
    Luger, Selina M.
    Litzow, Mark R.
    Tallman, Martin S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : 308 - 312
12345